


Visual presentation of the data presented in :
working document

Gautret et al. (2020) Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
International Journal of Antimicrobial Agents – In Press 17 March 2020 – DOI : 10.1016/j.ijantimicag.2020.105949

QUALITY OF DATA




- precise data (e.g. viral status 31)
- vague data (e.g. viral status positive)
- ambiguous data (difficult to interpret / unprecise)
- missing data

QUALITY OF DATA

p. 7

... Patients were seen at baseline for enrolment, initial data collection and treatment at day-0, and again for **daily follow-up during 14 days**. Each day, patients received a standardized clinical examination and when possible, a nasopharyngeal sample was collected. ...




patient

- precise data (e.g. viral status 31)
- vague data (e.g. viral status positive)
- ambiguous data (difficult to interpret / unprecise)
- missing data


patients lost in survey

- patient transferred to intensive care unit
- patient died
- other

OVERALL NUMBER OF PATIENTS




OVERALL NUMBER OF PATIENTS




OVERALL NUMBER OF PATIENTS

age - female patients age - male patients




CONTROL PATIENTS

age - female patients age - male patients



HYDROXYCHLOROQUINE TREATED PATIENTS

age - female patients age - male patients



p. 10


... Hydroxychloroquine-treated patients were older than control patients
(51.2 years vs. 37.3 years). ...

37,375
(average age of the case study patients)

51,2
(average age of hydroxychloroquine-treated patients)


CONTROL PATIENTS

age - female patients age - male patients




HYDROXYCHLOROQUINE TREATED PATIENTS

age - female patients age - male patients






OVERALL NUMBER OF PATIENTS

age - female patients age - male patients



p.10




... **No significant difference was observed between hydroxychloroquine-treated patients and control patients with regard to gender, clinical status and duration of symptoms prior to inclusion (Table 1).** ...




average age = 37,375


age - female


age - male




clinical status

 asymptomatic

 upper respiratory tract infection (URTI) - rhinitis, pharyngitis, or isolated low-grade fever and myalgia

 lower respiratory tract infections (LRTI) - symptoms of pneumonia or bronchitis


CONTROL PATIENTS











HYDROXYCHLOROQUINE TREATED PATIENTS



OVERALL NUMBER OF PATIENTS




6th day

-  asymptomatic at the beginning of treatment
-  upper respiratory tract infection (URTI) at the beginning of treatment - rhinitis, pharyngitis, or isolated low-grade fever and myalgia
-  lower respiratory tract infections (LRTI) at the beginning of treatment - symptoms of pneumonia or bronchitis
-  negative PCR - hydroxychloroquine treated patients
-  negative PCR – hydroxychloroquine and azithromycin combination treated patients
-  patients transferred to intensive care unit (day2, 3, 4)
-  patient died (day 3)
-  patients lost in survey other cases


negative PCR (CT (cycle threshold) value ≥ 35)
 Cts < 29 are strong positive reactions indicative of abundant target nucleic acid in the sample
 Cts of 30-37 are positive reactions indicative of moderate amounts of target nucleic acid
 Cts of 38-40 are weak reactions indicative of minimal amounts of target nucleic acid
 [Neetu Prince, *What does delta Ct value in PCR mean?*, Christian Medical College Vellore, CMCH-Vellore · Department of Physiology, <[## CONTROL PATIENTS](https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=11&cad=rja&uact=8&ved=2ahUKEwjpcOr3-voAhUN1RokHWHBA_kQFjAKegQIAhAB&url=https%3A%2F%2Fwww.wvdl.wisc.edu%2Fwp-content%2Fuploads%2F2018%2F05%2FWhat-does-CTmeanfinahandoutJanuary2014.pdf&usq=AOvVaw0uqXbM-PPgPWOQTYRvyU0m0>https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=11&cad=rja&uact=8&ved=2ahUKEwjpcOr3-voAhUN1RokHWHBA_kQFjAKegQIAhAB&url=https%3A%2F%2Fwww.wvdl.wisc.edu%2Fwp-content%2Fuploads%2F2018%2F05%2FWhat-does-CTmeanfinahandoutJanuary2014.pdf&usq=AOvVaw0uqXbM-PPgPWOQTYRvyU0m0>, consultation 14/04/2020]</p>
</div>
<div data-bbox=)

age - female patients age - male patients



HYDROXYCHLOROQUINE TREATED PATIENTS


age - female patients age - male patients



unknown sex and age of a patient

OVERALL NUMBER OF PATIENTS


age - female patients age - male patients



unknown sex and age of a patient

CONTROL PATIENTS

PCR




incomplete qualitative data (10/16)

day

PCR

CONTROL PATIENTS

HYDROXYCHLOROQUINE TREATED PATIENTS




PCR

CONTROL PATIENTS

HYDROXYCHLOROQUINE TREATED PATIENTS

HYDROXYCHLOROQUINE AND AZITHROMYCIN COMBINATION TREATED PATIENTS




incomplete qualitative data (10/16)


- intensive care
- intensive care
- intensive care
- died
- lost in survey other cases

day


Control patients par age




Série1 ■ Série2




Titre du graphique



Titre du graphique



Treated patients



	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
Série1	37	38	39	40	41	42	34	22	19	30	28	17	32	21	33	26	31	18	25	35	20	36	27	23	24	29
Série2	0	0	0	0	0	0	20	24	25	33	42	44	48	49	50	53	53	54	54	54	59	60	63	81	85	87

No of patiency


Série1 ■ Série2

- 50+** **7** **26,92 %**
- ?** **6** **23,07%**
- 40+** **4** **15,38 %**
- 20+** **3** **11,53%**
- 80+** **3** **11,53 %**
- 60+** **2** **7,69 %**
- 30+** **1** **3,84 %**

70+

19-

all patients by age



		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42
Série1		37	38	39	40	41	42	1	4	2	3	14	5	34	12	16	22	19	30	15	28	17	13	7	32	21	33	26	31	18	25	35	20	36	9	27	6	10	8	11	23	24	29
Série2		0	0	0	0	0	0	10	10	12	14	16	20	20	23	23	24	25	33	42	42	44	45	46	48	49	50	53	53	54	54	54	59	60	62	63	65	66	69	75	81	85	87

- 19-
- 20+
- 30+
- 40+
- 50+
- 60+
- 70+
- 80+

Série1 Série2